Duke University School of Medicine
A panel of expert cardiologists share their concluding thoughts on management of polyvascular disease in clinical practice.
Unmet Needs and Emerging Approaches to Management of Polyvascular Disease
Cardiologists share unmet needs and emerging approaches to management of patients with polyvascular disease.
VOYAGER Trial and DPI in Clinical Practice
Manesh Patel, MD, reviews VOYAGER trial data and expert cardiologists share where they use DPI [dual pathway inhibition] in their practices.
COMPASS Trial for CAD and PAD
Expert cardiologists discuss data from COMPASS trial and the role of rivaroxaban and low-dose aspirin in treatment of patients with CAD and PAD.
Access to and Awareness of DPI for Polyvascular Disease
Sahil Parikh, MD, shares how lack of access to or awareness of DPI [dual pathway inhibition] causes many practices and health care providers to face a challenge in treating CAD [coronary artery disease].
Direct Oral Anticoagulants and Dosing
Drs Patel and Bhatt discuss importance of correct dosing of direct oral anticoagulants in treatment of cardiovascular diseases.
Dual Pathway Inhibition in Coronary Artery Disease
Expert cardiologists provide an overview of dual pathway inhibition, modulation of thrombotic risk and treatment of CAD.
Risk-Benefit Analysis in Treatment Selection in CAD
Dr Amy Pollak shares her thoughts on risk-benefit analysis when evaluating patients with high thrombotic/bleeding risk and treatment selection.
Stents in Treatment of CAD and PAD
Dr Eric Secemsky discusses how use of stents has evolved over the years in treatment of polyvascular disease.
Dual Antiplatelet Therapy in CAD
Dr Manesh Patel and other experts discuss the role of dual antiplatelet therapy (DAPT) in treatment of coronary artery disease.
Regimen Intensification in Polyvascular Disease
Drs Marc Bonaca and Deepak Bhatt discuss the role of therapy intensification when managing high-risk patients with polyvascular disease.
Guidelines and Management of Patients With Polyvascular Disease
Expert cardiologists discuss CAD guidelines and approaches to management of patients with polyvascular disease.
Provider Engagement and Screening
Dr Sahil Parikh and other experts discuss engagement of cardiologists in patients diagnosed with polyvascular disease and challenges in screening patients.
Screening for Polyvascular Disease
Dr Amy Pollak and other experts discuss their recommendations for screening for CAD and PAD in asymptomatic patients.
Overview of Polyvascular Disease and Coronary Artery Disease
Drs Marc Bonaca and Manesh Patel provide an overview of Polyvascular Disease and prevalence of coronary artery disease and peripheral artery disease.
Treatment Decisions and its Relation to Patient Accessibility
Final thoughts from expert KOLs regarding treatment decisions and how they relate to patient accessibility when manage dyslipidemia.
Shared Decision Making and Value-Based Care
Importance of shared decision making and value-based care when making treatment decisions for cardiovascular patients.
Bempedoic Acid for Lipid Lowering
Bempedoic acid monotherapy and its combination with ezetimibe for lipid lowering in patients intolerant to statins.
Dietary and Lifestyle Modifications in Lipid Management
Role of dietary and lifestyle modifications as part of lipid management.
Statins as the Standard of Care for Patients With Dyslipidemia
Dean Karalis, MD, provides expertise on the appropriate use of statins based on primary and secondary prevention.
Cost-Effectiveness of Inclisiran for Treating Hyperlipidemia
Expert cardiologists express support for the uptake in the use of inclisiran once approved based on the cost-effectiveness.
Challenging Guidelines in a Non-ACS Population
Norman Lepor, MD, FACC, FAHA, FSCAI, challenges the use of ezetimibe before a PCSK9 inhibitor in a population with no acute coronary syndrome.
Inclisiran in the Current Treatment Landscape for Lipid Lowering
Key opinion leaders in cardiology share their perspectives on using inclisiran post FDA approval within the current treatment landscape based on guidelines.
Phase 3 ORION Trials for Inclisiran
Norman Lepor, MD, FACC, FAHA, FSCAI, reviews the efficacy of inclisiran in terms of LDL reduction based on the pooled analysis of the phase 3 ORION trials.
Emerging Use of Inclisiran as Adjunct Therapy in Hyperlipidemia
Experts review in detail the emerging use of inclisiran as an adjunct therapy for lipid lowering in patients with high cholesterol.
EPA in the Prevention of CV Risk
Panel of experts discuss the use and safety profile of purified icosapent ethyl compound (EPA) in prevention of CV risk.
Outcomes and Practical Implications of Newer Agents
Cardiologists briefly review the outcomes data and practical implications of novel treatment options for hyperlipidemia.
Mechanism of Action of Inclisiran in Lipid Lowering
Manesh Patel, MD, briefly addresses the mechanism of action of inclisiran as an adjunct therapy for lipid lowering in patients with high cholesterol.
Aggressive LDL Lowering in High-Risk Patients
Dean Karalis, MD, provides his perspective on intensive LDL lowering in patients with risk for high cholesterol and related disorders.
High Cholesterol Versus Familial Hypercholesterolemia
Linda Hemphill, MD, shares her views on how familial hypercholesterolemia impacts the assessment of high-risk patients.
2 Clarke Drive Cranbury, NJ 08512